Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide and is frequently limited by systemic toxicity, drug resistance, and high rates of recurrence. The authors designed a multi‑target strategy to address these challenges by creating hybrid molecules that combine activity against the Adenosine A2A receptor (A2AR) and the Epidermal Growth Factor Receptor (EGFR). The conceptual rationale was that convergent inhibition at these targets would modulate the PI3K/AKT survival axis and reduce apoptotic resistance in CRC cells, thereby improving therapeutic efficacy relative to single‑target agents.
A molecular hybridization approach was applied, leveraging pharmacophores from the EGFR inhibitor Gefitinib and the A2AR antagonist Tozadenant to generate three series of thiazolyl‑pyrazoline hybrids. These series were evaluated using molecular docking as part of an iterated multidisciplinary pipeline that guided synthesis and biological testing. The abstract reports lead identification from this pipeline but does not provide synthetic schemes, full structure‑activity relationship tables, or detailed docking scores in the abstract; those specifics are available only in the full text.
Biological testing identified two lead molecules with pronounced activity against the human colorectal cancer cell line Caco2. Compound 6aii demonstrated exceptional cytotoxicity with an IC50 of 0.037 ± 0.10 μM, while compound 10b had an IC50 of 0.6125 ± 0.13 μM in Caco2 cells. Enzyme inhibition assays against the intended molecular targets showed low‑to‑submicromolar potency: EGFR inhibition with IC50 values in the reported range of 1.53 ± 0.12 to 8.37 ± 0.03 μM, and A2AR inhibition in the range 0.037 ± 0.21 to 0.6125 ± 0.15 μM. These data suggest stronger potency on the A2AR axis for selected analogs and measurable EGFR kinase inhibition at micromolar concentrations.
Mechanistic investigations reported that the hybrids induced cell cycle perturbations, specifically arrest in S and G2/M phases. Gene expression analyses indicated a shift in apoptotic balance: upregulation of pro‑apoptotic markers Caspase‑3, TP53, and Bax, and downregulation of the anti‑apoptotic gene Bcl‑2. Together, these findings are consistent with restored apoptotic signaling and indicate the hybrids act to both inhibit proliferation and promote programmed cell death in CRC cells.
The study evaluated downstream signaling of A2AR, reporting that compound 6ii produced the lowest intracellular cAMP levels among tested analogs, which is consistent with effective antagonism of A2AR‑mediated signaling. The abstract links suppressed cAMP expression to functional inhibition of the A2AR pathway; detailed quantitative comparisons beyond the stated lowest effect and the specific assay conditions are not provided in the abstract.
In vivo validation was performed using an azoxymethane (AOM)‑induced colorectal cancer mouse model. Treatment with the thiazolyl‑pyrazoline hybrids reportedly restored colonic crypt architecture and suppressed EGFR overexpression in the treated animals. The abstract also notes favorable safety readouts with respect to liver serum enzyme levels. The PubMed abstract does not report dosing regimens, group sizes, duration of treatment, histologic scoring methods, or complete safety panels; these methodological and quantitative details are expected to be described in the full article.
The authors conclude that dual A2AR/EGFR targeting with thiazolyl‑pyrazoline hybrids provides a promising preclinical framework for multi‑target drug discovery in advanced colorectal cancer. Lead compounds (notably 6aii and 10b) combined potent in vitro cytotoxicity in Caco2 cells, target inhibition at low‑to‑submicromolar concentrations, restoration of apoptotic gene balance, and supportive in vivo efficacy and liver safety signals in an AOM model. The abstract emphasizes the translational potential but does not supply full experimental detail in this summary; readers should consult the full text for complete synthetic methods, comprehensive pharmacology, statistical analyses, and any additional safety or efficacy endpoints.